These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10855392)

  • 1. [Antibiotic therapy in cystic fibrosis. I. Pharmacologic specifics of antibiotics].
    Sermet-Gaudelus I; Hulin A; Ferroni A; Silly C; Gaillard JL; Berche P; Lenoir G
    Arch Pediatr; 2000 May; 7(5):519-28. PubMed ID: 10855392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.
    de Groot R; Smith AL
    Clin Pharmacokinet; 1987 Oct; 13(4):228-53. PubMed ID: 3311531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.
    Ciofu O; Mandsberg LF; Wang H; Høiby N
    FEMS Immunol Med Microbiol; 2012 Jul; 65(2):215-25. PubMed ID: 22540844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diffusion of beta-lactam antibiotics through mixed gels of cystic fibrosis-derived mucin and Pseudomonas aeruginosa alginate.
    Bolister N; Basker M; Hodges NA; Marriott C
    J Antimicrob Chemother; 1991 Mar; 27(3):285-93. PubMed ID: 1903787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibiotic inhalation in cystic fibrosis. A review of the literature].
    Steinkamp G
    Monatsschr Kinderheilkd; 1991 Feb; 139(2):73-80. PubMed ID: 1903843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti Pseudomonas aeruginosa antibiotic therapy in cystic fibrosis (exclusion of macrolides)].
    Sermet-Gaudelus I; Ferroni A; Vrielinck S; Lebourgeois M; Chedevergne F; Lenoir G
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S30-43. PubMed ID: 17370394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin pharmacokinetics in adult cystic fibrosis.
    Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL
    Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS
    Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics.
    Horrevorts AM; Driessen OM; Michel MF; Kerrebijn KF
    Chest; 1988 Aug; 94(2 Suppl):120S-125S. PubMed ID: 3293937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.
    Gaillard JL; Cahen P; Delacourt C; Silly C; Le Bourgeois M; Coustère C; de Blic J; Lenoir G; Scheinmann P
    Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):291-6. PubMed ID: 7649191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?
    Bos AC; Passé KM; Mouton JW; Janssens HM; Tiddens HA
    J Cyst Fibros; 2017 Jan; 16(1):13-23. PubMed ID: 28254026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.
    Lindsay CA; Bosso JA
    Clin Pharmacokinet; 1993 Jun; 24(6):496-506. PubMed ID: 8513651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients.
    Thompson RZ; Martin CA; Burgess DR; Rutter WC; Burgess DS
    J Cyst Fibros; 2016 Sep; 15(5):660-3. PubMed ID: 27132188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa.
    Nair CG; Chao C; Ryall B; Williams HD
    Lett Appl Microbiol; 2013 Feb; 56(2):149-54. PubMed ID: 23206221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.